Supply Chain

There is no doubt that drug shortages are a detriment to the pharma supply chain, but how commonplace were they during the COVID era?

The move features the launch of an innovation center revolving around cell and gene services.

Session addresses the challenges of implementing autologous/allogeneic cell gene therapies into scalable networks.

A panel uncovers the value in meeting carbon-neutral goals by 2030.

Masterclass session addresses looking beyond a dashboard by added capabilities with added value.

Wattala warehouse is expected to offer both export consolidation and 3PL services for trade routes that link Africa, Asia, and Europe.

If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.

The program recognizes organizations that prioritize the highest standards of care when it comes to the handling and transportation of goods in the healthcare space.

The program intends to address pharmacy deserts, which are predominantly found in underserved communities.

Year-on-year growth in demand is strong, according to the IATA.

Although time has welcomed novel advances in the space, new challenges pertaining to data and the physical technology, along with visibility and sustainability, are emerging.

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

Syneos Health's Kim Plesnarski uncovers the key issues that customers are currently trying to address, including the retail shift from small-molecule products to biologics.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

Five of the company’s vaccines are currently in Phase III.

The new option will help patients receive life-saving medications at an even quicker rate.

The organizations conducted an in-depth study of the program over the course of two years, publishing a white paper on the findings.

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

Under the group purchasing agreement, the serialization business will be the sole provider of DSCSA services for Premier’s 4,300-plus hospital and health system network.

Steven H. Collis, who currently holds the position, will transition to executive chair of the board.

The Asia-Pacific location is expected to provide serialization solutions for counterfeit medication entering the pharma supply chain.

A sit-down with Groovy Singh, CEO of Bright Green Corporation, who describes the waves in the global supply chain the company is making after being authorized to grow cannabis, along with cannabis-related products.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

The CDC urges healthcare providers to preserve their current supply.

With its aims to protect healthcare consumers against the dangers of counterfeit, contaminated, stolen or otherwise harmful drugs, the DSCSA represents a significant step forward in securing the pharmaceutical supply chain.

The offering reportedly helps avoid product quarantine.

Current production of Qdenga will increase to 50 million doses a year.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.

Strategic and proactive thinking are vital in providing supply chain leaders with an opportunity to shift their focus to a more holistic, value-centered approach.